TP53 and prostate cancer: In a recent study, it was found that in prostate cancer with p53 and Rb deletion, overexpression of the transcription factor SOX2 can mediate lineage plasticity, thereby enabling prostate cancer to evade targeted therapies and lead to CRPC (90).